Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The objective of this prospective, single-center randomized controlled trial is to identify the optimal adjuvant intravesical therapy in patients with intermediate risk (IR) non muscle invasive bladder cancer by comparing two commonly utilized intravesical regimens; intravesical immunotherapy (BCG) and intravesical chemotherapy.
Epistemonikos ID: 0863e2ef7d74d8c37ee85977976f6bd224d25506
First added on: May 09, 2024